Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Key Stats

• Today's Range: $7.28 to $8.40
• 50-Day Range: $5.80 to $9.23
• 52-Week Range: $5.51 to $10.16
• Volume: 115,062 shs
• Average Volume: 42,603 shs
• Market Capitalization: $152.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACTU Stock Analysis - Frequently Asked Questions

How have ACTU shares performed this year?

Actuate Therapeutics' stock was trading at $8.61 at the start of the year. Since then, ACTU shares have decreased by 6.9% and is now trading at $8.02.
View the best growth stocks for 2024 here.

How were Actuate Therapeutics' earnings last quarter?

Actuate Therapeutics (NASDAQ:ACTU) released its quarterly earnings results on Tuesday, September, 24th. The company reported ($4.20) earnings per share for the quarter.

When did Actuate Therapeutics IPO?

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering (IPO) on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners served as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

When did Actuate Therapeutics' quiet period expire?

Actuate Therapeutics' quiet period expired on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During Actuate Therapeutics' quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Actuate Therapeutics' major shareholders?

Top institutional shareholders of Actuate Therapeutics include KG&L Capital Management LLC (0.06%). Insiders that own company stock include Equity Cof Lp Bios, Todd S Thomson and Leslie W Kreis.
View institutional ownership trends.

How do I buy shares of Actuate Therapeutics?

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Actuate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 9/24/2024
• Today: 11/01/2024
• Next Earnings (Estimated): 12/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACTU
• Previous Symbol: NASDAQ:ACTU
• CUSIP: N/A
• CIK: 1652935
• Web: N/A
• Phone: (847) 986-4190
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 19,530,000
• Free Float: N/A
• Market Cap: $156.63 million
• Optionable: N/A
• Beta: N/A